GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
65.04
-2.17 (-3.23%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close67.21
Open67.52
Bid0.00 x 1800
Ask0.00 x 1100
Day's Range64.91 - 67.53
52 Week Range60.32 - 79.61
Volume8,876,391
Avg. Volume6,474,109
Market Cap82.702B
Beta (3Y Monthly)1.15
PE Ratio (TTM)14.35
EPS (TTM)4.53
Earnings DateJul 30, 2019
Forward Dividend & Yield2.52 (3.75%)
Ex-Dividend Date2019-06-13
1y Target Est80.19
Trade prices are not sourced from all markets
  • Congress set to vote on repeal of 'Cadillac tax'
    Yahoo Finance Video5 days ago

    Congress set to vote on repeal of 'Cadillac tax'

    Yahoo Finance’s Adam Shapiro, Julie Hyman, Scott Gamm, Anjalee Khemlani, and Kristin Myers discuss.

  • Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
    Zacks3 days ago

    Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

    While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.

  • MarketWatch3 days ago

    Gilead licensing three pre-clinical programs from Novartis

    Gilead Sciences Inc. has licensed three pre-clinical anti-viral programs from rival pharmaceutical giant Novartis AG , the companies announced Friday. Under the terms of the agreement, Gilead will get exclusive rights to develop and commercialize several small molecules that have the potential to treat human rhinovirus, influenza and herpes. Novartis will receive an upfront payment, the amount for which was not disclosed, and will be eligible to get an additional $291 million in potential milestone payments and royalties on annual net sales. Shares of both Gilead and Novartis were up slightly in premarket trade. Gilead's stock has gained 7.5% in the year to date through Thursday, while Novartis shares have gained 24.2%. The S&P 500 has gained 19.5%.

  • Business Wire3 days ago

    Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis

    Gilead Sciences, Inc. (GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales.

  • 10 Stocks with Upside Momentum for 2Q Earnings
    Investopedia3 days ago

    10 Stocks with Upside Momentum for 2Q Earnings

    Morgan Stanley has identified the stocks with the most positive momentum going into the 2Q 2019 earnings reporting season.

  • These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger
    Investor's Business Daily4 days ago

    These 5 Firms Could Buy Celgene's Otezla Ahead Of The Bristol Merger

    Gilead Sciences should acquire Celgene's psoriasis drug Otezla, but only for less than $9.6 billion, analysts said Thursday. Celgene is divesting Otezla ahead of its Bristol-Myers merger.

  • 3 Top Healthcare Stocks to Buy Right Now
    Motley Fool4 days ago

    3 Top Healthcare Stocks to Buy Right Now

    These three healthcare stocks are worth checking out right now. Here's why.

  • Cambridge startup Kronos raises $105M in one of the biggest Series A rounds of the year
    American City Business Journals4 days ago

    Cambridge startup Kronos raises $105M in one of the biggest Series A rounds of the year

    Kronos Bio CEO Norbert Bischofberger and board member Arie Belldegrun contributed to the Series A round, which is one of the largest in the industry this year.

  • Business Wire4 days ago

    Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019

    Gilead Sciences, Inc. today announced that new data from the company’s HIV research and development programs will be presented at the 10th International AIDS Society Conference on HIV Science being held in Mexico City from July 21-24.

  • Gilead Sciences (GILD) Stock Moves -0.03%: What You Should Know
    Zacks5 days ago

    Gilead Sciences (GILD) Stock Moves -0.03%: What You Should Know

    Gilead Sciences (GILD) closed at $66.92 in the latest trading session, marking a -0.03% move from the prior day.

  • Top Gilead execs leaving as new CEO continues remake of drug maker
    American City Business Journals5 days ago

    Top Gilead execs leaving as new CEO continues remake of drug maker

    Three executives, in addition to the earlier-announced departure of CFO Robin Washington, will leave Gilead over the next few months.

  • Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
    Zacks5 days ago

    Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study

    Key highlights of the past week include collaborations and other pipeline updates.

  • MarketWatch5 days ago

    Gilead's Chief Scientific Officer to leave next month

    Gilead Sciences Inc's Chief Scientific Officer John McHutchison will leave the company next month, the company announced Wednesday. McHutchison, who is also Gilead's head of research and development, joined the pharmaceutical giant in 2010 and was named chief scientific officer in March 2018. During his time at Gilead, he oversaw the development of several hepatitis B and C treatments, as well as the company's expansion into oncology with the development of Zydelig. Gilead also announced other changes to its senior leadership team: Chief Patient Officer Greg Alton and Executive Vice President of Human Resources Katie Watson will be leaving, as well. Jyoti Mehra, currently vice president of human resources, will take Watson's place. Shares of Gilead fell 0.4% in premarket trade on the news. The stock has gained 7% in the year to date through Tuesday, while the S&P 500 has gained 19.8%.

  • Business Wire5 days ago

    Gilead Sciences Announces Changes to Senior Leadership Team

    Gilead Sciences, Inc. (GILD) announced today changes to the company’s senior leadership team. Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing Gilead. Jyoti Mehra has been named Executive Vice President, Human Resources, and will assume responsibility for the worldwide HR function.

  • Business Wire5 days ago

    Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company

    Gilead Sciences, Inc. (GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month. Dr. McHutchison joined Gilead in 2010 and under his leadership, Gilead has developed five medicines that have been used by more than 3.2 million people around the world for the curative treatment of chronic hepatitis C, and treatment of chronic hepatitis B. He also oversaw the company’s expansion into oncology with the development of Gilead’s first cancer medicine, Zydelig® (idelalisib). During his tenure, he has been responsible for broadening and overseeing the company’s Research and Development pipeline, advancing candidates in new therapeutic areas, including oncology, cell therapy and inflammation.

  • Gilead's Galapagos Deal: What It Means for Investors
    Motley Fool5 days ago

    Gilead's Galapagos Deal: What It Means for Investors

    Here's what Gilead's getting with its $5.1 billion Galapagos collaboration.

  • Business Wire6 days ago

    Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019

    Gilead Sciences, Inc. (GILD) announced today that its second quarter 2019 financial results will be released on Tuesday, July 30, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2019 and provide a business update. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 8696029 to access the call.

  • Doctor Who Sold $12 Billion Drug Firm Eyes Biotech Property
    Bloomberg6 days ago

    Doctor Who Sold $12 Billion Drug Firm Eyes Biotech Property

    (Bloomberg) -- A deal-making cancer doctor who sold his pharmaceutical company for almost $12 billion is launching a real estate venture to bolster the growth of the biotechnology industry.Arie Belldegrun’s family office, Bellco Capital, has entered into a joint venture with New York-based real estate developer Tishman Speyer to start Breakthrough Properties, the companies said Tuesday in a statement. The venture said it bought its first property, a 1-acre (0.4 hectare) development site in Boston’s Seaport District, for $80 million, and is exploring other acquisitions in the area as well as in San Francisco.“This came out of necessity,” Belldegrun said in a telephone interview. “I realized that there’s a significant need for an ecosystem in life sciences where scientists can work and interact.”Belldegrun, 69, is a UCLA-based cancer researcher and surgeon who’s emerged as a serial entrepreneur and venture capitalist. He sold Kite Pharma, which develops genetically engineered cancer treatments, in 2017 to Gilead Sciences Inc. for $11.9 billion and since then has helped launch Vida Ventures to start more pharma companies.Boston SiteBreakthrough Properties will provide various business development services to help tenants grow, Belldegrun said. Vida Ventures, his venture capital arm, may also take stakes in the biotech firms. The Seaport District site comes with 250,000 square feet (23,200 square meters) of development rights and is expected to be finished by 2021, according to the statement.Breakthrough’s chief executive officer is Belldegrun’s son Dan, who worked for Tishman Speyer for several years. Belldegrun’s wife, Rebecka, who is also a doctor, manages Bellco Capital, the family office formed in 2003.The venture -- a foray into life-sciences development for Tishman Speyer -- will face competition from companies such as Alexandria Real Estate Equities Inc., which built its business around catering to biotech tenants. About a quarter of Alexandria’s 250 properties are in the Boston area, while the remainder are spread across U.S. cities including San Francisco, New York and San Diego.Breakthrough has its sights set on some of those cities and ultimately has plans to expand globally, according to Tishman Speyer CEO Rob Speyer.“The last thing a life-sciences company should be worrying about is real estate, and we can take that concern off the table for them,” Speyer said in an interview. “We’re going to focus on strategic cities that have biotech companies, leading universities and quality housing options.”Tishman Speyer, whose properties include New York’s Rockefeller Center, last year sold a 13-story building in Boston’s burgeoning Seaport District for $450 million, setting a record for an office transaction in the city.(Adds potential for competition with Alexandria in seventh paragraph.)To contact the reporters on this story: Michael McDonald in Boston at mmcdonald10@bloomberg.net;Lily Katz in New York at lkatz31@bloomberg.netTo contact the editors responsible for this story: Alan Mirabella at amirabella@bloomberg.net, Josh Friedman, Christine MaurusFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • Company News for Jul 16, 2019
    Zacks6 days ago

    Company News for Jul 16, 2019

    Companies In The News Are: SYMC,AVGO,GLPG,GILD,BA,AAL,UNIT

  • Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
    Business Wire6 days ago

    Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility

    Kite, a Gilead Company , today announced plans for a new 67,000-square-foot facility in Oceanside, California, dedicated to the development and manufacturing of viral vectors, a critical starting material in the production of cell therapies.

  • 3 Soaring Biotech Stocks With More Fuel in the Tank
    Motley Fool6 days ago

    3 Soaring Biotech Stocks With More Fuel in the Tank

    Despite already massive gains this year, shares of these drugmakers could keep on climbing.

  • Moody's7 days ago

    Gilead Sciences, Inc. -- Moody's: Gilead's collaboration with Galapagos credit positive

    Moody's Investors Service commented that Gilead Sciences, Inc.'s new research and development collaboration with Galapagos NV is credit positive for Gilead. There are no changes to Gilead's A3 existing senior unsecured rating or stable rating outlook. For additional information please refer to Moody's issuer comment on Gilead available on www.moodys.com.

  • GuruFocus.com7 days ago

    Wall Street Mixed on Monday

    Galapagos skyrockets to an all-time high Continue reading...

  • What Happened in the Stock Market Today
    Motley Fool7 days ago

    What Happened in the Stock Market Today

    From failed takeover talks to a massive new partnership, see why these stocks were on the move on a quiet day for the broader markets.

  • Nasdaq Today: Bitcoin & Libra; What’s Broadcom Doing?
    InvestorPlace7 days ago

    Nasdaq Today: Bitcoin & Libra; What’s Broadcom Doing?

    There will be a bundle of earnings reports that start to roll out this week. On Monday morning we had a few, but it's about to get busy in the second half of July. Given how much is set to come out over the next few weeks, it was a relatively quiet day on Wall Street Monday. We saw an 0.17% gain in the Nasdaq today, followed by slight gains for the S&P 500 and Dow Jones.Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat said, there's a lot individual news to dig through. Bitcoin, Libra and CryptoThe bitcoin market has been wildly volatile lately, hasn't it? Bitcoin prices ran from $5,500 at the start of May to more than $8,700 by June 1st. Just a few weeks later it was north of $13,000. It topped out around $13,600, before it promptly fell to just under $10,000. Crypto bulls said it was an opportunity. Bears argued it was a blowoff top and it was coming back down. Another run to $13,000 earlier this month was again met with sellers as bitcoin prices dropped back down to $10,000. * 7 Dependable Dividend Stocks to Buy I'll stop the onslaught of price history, but it's sort of necessary for an asset like bitcoin. Put simply, this thing is volatile. Perhaps we're entering a range-bound trade, between $10,000 and $13,000. At the very least, traders now have a few lines in the sand, where a move above resistance or below support could spell a further move in that direction. The advances in bitcoin have helped give a boost to Facebook (NASDAQ:FB) stock, even as it's drawn the ire of regulators for its Libra cryptocurrency. Congress has asked Facebook to hold off on Libra until it knows more. It's drawn comments from the president, while U.S. Treasury Secretary Steven Mnuchin said the Treasury has serious concerns over Libra.For its part, Facebook -- which will reportedly settle with the FTC for $5 billion -- said it will wait until it has regulatory support before launching. Heard at the Nasdaq TodayShares of Gilead Sciences (NASDAQ:GILD) were on the move Monday, rising 2.7% and closing at $68.07. It will invest $5.1 billion in Galapagos (NASDAQ:GLPG), increasing its stake in the company from 12.2% to 22%. Galapagos will now see if shareholders approve an eventual stake increase to 29.9%. Given today's action, it's hard to see shareholders saying no, with GLPG stock rising more than 17% to new highs. Further, Gilead Sciences stock was upgraded to outperform at Wells Fargo. The analysts assigned an $88 price target, implying about 30% upside from current levels and signaling new 52-week highs should GILD stock get there. OK, so what's going on with Broadcom (NASDAQ:AVGO) and Symantec (NASDAQ:SYMC)? Broadcom was reportedly in talks to acquire SYMC. However, on Monday, shares of Symantec abruptly tumbled lower, falling over 10% on news that AVGO is no longer in talks to buy the company. However, the stock recovered off its initial lows -- and actually closed at session highs -- while AVGO stock rallied almost 3% on the news, before ending higher by just 1%. New reports say that Broadcom isn't walking away from the deal just yet. So what gives? This is just typical M&A drama. I don't know if Broadcom will pull the trigger for SYMC. Maybe the latter wanted even more money. Perhaps the terms weren't right. Either way, the market seems happy for AVGO to walk away, if that should be a sign of anything. Broadcom stock has been under pressure since the buyout news surfaced and rallied when it looked like the deal was off. Movers in the Nasdaq Today Click to EnlargeAlphabet's (NASDAQ:GOOGL, NASDAQ:GOOG) Google, as well as several social media sites have fallen under criticism that they display a political bias. Google's vice president of government affairs Karan Bhatia wrote an op-ed stating that the company does not have a bias and stated he will tell U.S. Senators that is the case as well. Social media is playing an enormous role in the distribution of political news, both real and fake. It's created a frenzy of both misinformation and information overload, drawing criticism from both political parties. No matter which side of the aisle readers stand on, they should be reading factually correct information, although tech companies haven't seemed to find a very good way to govern it thus far. Tesla (NASDAQ:TSLA) stock is hitting its highest levels since May, rising 3.4% on Monday on above-average volume. The stock is now running into prior support though, which acted as resistance a few months ago. The stock has to reclaim this area to really get the bullish train moving. Amazon's (NASDAQ:AMZN) much-awaited Prime Day is finally here, with sales going strong on Monday and Tuesday. The e-commerce retailer will pull in billions in revenue from the event and is drawing in competition from seemingly every online retailer (seriously, have you checked your inbox lately?) * 5 EV Stocks to Buy for Big Gains Over the Next Decade Target (NYSE:TGT), Costco (NASDAQ:COST), Home Depot (NYSE:HD) -- three strong retailers by the way -- have been hitting it hard, as has Walmart (NYSE:WMT), Best Buy (NYSE:BBY) and others. With a strong labor market, I would expect Amazon's Prime Day numbers to be solid this year. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long AVGO, GOOGL and AMZN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dependable Dividend Stocks to Buy * 10 Stocks Driving the Market to All-Time Highs (And Why) * 7 Short Squeeze Stocks With Big Upside Potential The post Nasdaq Today: Bitcoin & Libra; Whata€™s Broadcom Doing? appeared first on InvestorPlace.